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Abstract: Oxidative stress and inflammation play major roles in the pathogenesis of 
coronary heart disease including myocardial infarction (MI). The pathological progression 
following MI is very complex and involves a number of cell populations including cells 
localized within the heart, as well as cells recruited from the circulation and other tissues 
that participate in inflammatory and reparative processes. These cells, with their secretory 
factors, have pleiotropic effects that depend on the stage of inflammation and regeneration. 
Excessive inflammation leads to enlargement of the infarction site, pathological 
remodeling and eventually, heart dysfunction. Stem cell therapy represents a unique and 
innovative approach to ameliorate oxidative stress and inflammation caused by ischemic 
heart disease. Consequently, it is crucial to understand the crosstalk between stem cells and 
other cells involved in post-MI cardiac tissue repair, especially immune cells, in order to 
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harness the beneficial effects of the immune response following MI and further improve 
stem cell-mediated cardiac regeneration. This paper reviews the recent findings on the role 
of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated 
cardiac repair following ischemic heart disease, particularly acute MI and focuses 
specifically on mesenchymal, muscle and blood-vessel-derived stem cells due to their 
antioxidant and immunomodulatory properties. 
Keywords: stem cells; myocardial infarction; oxidative stress; inflammation; immune 
system; cardiac repair 
 
1. Introduction 
Cardiovascular disease is the leading cause of mortality in the world with over 17 million deaths in 
2008 alone [1], which is estimated to increase to over 23 million by 2030 and to remain the leading 
cause of deaths [2]. Coronary heart disease causes the majority of deaths in cardiovascular disease with 
myocardial infarction (MI) often leading to the development of heart failure. MI is caused by occlusion 
of a coronary artery, which leads to a deficiency of oxygen and nutrients at the site of infarction and 
the subsequent death of cardiomyocytes. The exposure of danger-associated molecular patterns 
(DAMPs) from dead cardiomyocytes, triggers the migration of neutrophils, monocytes, dendritic cells, 
lymphocytes and other cells with subsequent initiation of inflammation, oxidative stress, tissue 
regeneration and cardiac remodeling; however, the mechanisms behind these processes are still not 
fully understood [3–6].  
Stem cell therapy is considered a promising approach in treating coronary heart disease including 
MI due to the ability of stem cells and/or their secretory factors to influence host cell migration, 
cellular functions, cardiomyocyte survival, tissue regeneration and healing [7–9]. The use of stem cells 
and/or their secretory factors may lead to effective therapeutic approaches for reducing the infarct size, 
generating more functional heart tissue, eliminating heart failure and improving the life of patients  
who have suffered from MI. The current review highlights the role of oxidative stress and the  
immune system in pathogenesis of acute MI and focuses specifically on mesodermal stem cells, 
including mesenchymal, muscle and blood-vessel-derived stem cells, due to their antioxidant and 
immunomodulatory properties. 
2. Oxidative Stress and Inflammation Following Myocardial Infarction 
Oxidative stress and inflammation play major roles in tissue damage, clearance of cell debris, 
myocardial fibrosis, and remodeling of heart tissue following MI, although the details of the initiation, 
development and control of these processes have not been fully deciphered. In this section, we briefly 
review the sequence of events related to oxidative stress and inflammation mediated by the cells of the 
immune system to better understand possible therapeutic targets using stem cells or their factors 
described in the following sections.  
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MI causes necrosis and apoptosis of cardiomyocytes and exposure of DAMPs, which are molecules 
produced by stressed/damaged cells or extracellular matrix fragments, and initiate the innate immune 
response and inflammation [10]. The DAMPs that are involved in MI are mainly high motility group 
box 1 (HMGB1), heat shock proteins (HSPs), fibronectin and hyaluronan fragments (Figure 1). 
HMGB1, a chromatin binding protein located in the nucleus, which can be secreted from the stressed 
cells and form a heterodimer with IL-1β [11], stimulates the production of pro-inflammatory cytokines 
such as TNF-α, IL-1 and IL-6 by macrophages after binding to Toll-like receptor (TLR) 4 [12,13]. In 
addition, HMGB1 enhances cell migration by forming a heterocomplex with chemokine CXCL12, 
which is mediated by CXCR4, the receptor for CXCL12 [14]. HSP60, which is a stress protein 
released from cardiac myocytes after hypoxic shock, can induce the expression of pro-inflammatory 
cytokines TNF-α and IL-1β, activate caspase 3 and 8, as well as cause DNA fragmentation and 
apoptosis of cardiac myocytes by binding to TLR4 [15,16]. Both fibronectin and hyaluronan 
fragments, which are both constituents of the extracellular matrix, can activate the innate immune 
system by binding to TLR2 and TLR4 [17,18]. 
Figure 1. Schematic depiction of representative events following myocardial infarction 
(MI). MI causes the exposure of danger-associated molecular patterns (DAMPs), initiation 
of oxidative stress and inflammation, and can lead to the resolution of inflammation, 
reduction of oxidative stress, formation of scar tissue and left ventricular remodeling. 
Nevertheless, the pathological processes following MI are very complex with overlaps of 
depicted events and participation of additional cell types/secretory factors that are not 
included in this figure.  
 
DAMPs are recognized by TLR on the surface of cardiac myocytes, endothelial cells and cells of 
the immune system. TLR in humans were discovered by Madzhidov and colleagues [19] and are 
pattern recognition receptors and a part of the innate immune system. TLR4 plays a key role in the 
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response of the innate immune system following MI. Indeed, the TLR4 knockout animals 
demonstrated diminished inflammation, a reduction in the number of apoptotic cells and CD3+ T cells 
in the infarcted area, attenuated left ventricular remodeling and improved animal survival [20,21]. 
Similarly, the TLR2 knockout mice showed better survival, reduced fibrosis and downregulation of 
TGF-β expression in the heart tissue [22]. TLR binding results in the recruitment of myeloid 
differentiation primary response 88 (MyD88), and eventually, the translocation of NF-κB into the 
nucleus and activation of chemokine and pro-inflammatory cytokine gene expression [23,24]. 
Furthermore, components of the apoptotic cardiac myocytes and DAMPs can activate the complement 
system that plays an active role in the pathogenesis of MI [25,26]. Cardiac myocytes express the 
receptor to C5a, which is up-regulated following MI, and antibodies against C5a decrease infarct size, 
reduce vascular permeability and adherence of neutrophils to endothelial cells in experimental models 
of MI [27,28].  
Oxidative stress, which results from the excessive production of reactive oxygen species (ROS) and 
the inability of the antioxidant system to neutralize them, plays a pivotal role in damaging and 
remodeling cardiac tissue. ROS are oxygen-containing compounds such as superoxide anion, hydroxyl 
radical and hydrogen peroxide, mainly produced in the heart by neutrophils, cardiac myocytes and 
endothelial cells. Myocardial ischemia leads to increased ROS activity through two mechanisms: (1) a 
decrease in the defensive activity including reduced mitochondrial superoxide dismutase function and 
diminished reserve of reduced glutathione, and (2) an increase in the offensive action including 
elevated production of free radicals and toxic oxygen metabolites, especially following the  
post-ischemic reperfusion [29]. ROS cause cell apoptosis by breaking down DNA and stimulating  
pro-apoptotic signaling pathways. In addition, ROS induce the production of pro-inflammatory 
cytokines and matrix metalloproteases (MMP) that further aggravate inflammation and pathological 
remodeling. The regulation of gene expression by ROS is mediated by NF-κB, AP-1 and peroxisome 
proliferator-activated receptor. Oxidative stress causes endothelial cell dysfunction, up-regulation of 
adhesion molecules, secretion of pro-inflammatory cytokines, and increase of endothelial cell 
permeability and migration of neutrophils [30,31]. 
Neutrophils are the first cells of the immune system that migrate to the site of injury in the heart and 
produce ROS and proteolytic enzymes (Figure 1). The migration of neutrophils is mediated by  
up-regulated P-selectin (CD62P) and E-selectin (CD62E) on the surface of endothelial cells [32] and 
up-regulated L-selectin (CD62L) on the surface of neutrophils [33] as well as an enhanced ability of 
intercellular cell adhesion molecule-1 (ICAM-1) on the surface of endothelial cells to bind neutrophils [34]. 
Double knockout mice for P-selectin and ICAM-1 demonstrated a significantly reduced migration of 
neutrophils without affecting the infarct size [35]. C5, a factor of activated complement, and IL-8 play 
important roles in neutrophil chemotaxis [36]. The recruited neutrophils ingest dead cell debris, 
produce MMP to degrade the extracellular matrix, release ROS, and secrete proteolytic enzymes and 
pro-inflammatory cytokines that further aggravate inflammation. Neutrophils can bind cardiac 
myocytes via ICAM-1 and directly damage them by producing ROS and proteolytic enzymes [37]. In 
addition, neutrophils contribute to the initiation of monocyte migration by up-regulating adhesion 
molecules and by producing chemotactic factors. Neutrophils secrete granules that up-regulate the 
expression of vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 on the surface of endothelial 
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cells, stimulate production of IL-8 and macrophage inhibitory protein-1a (MIP-1a) by monocytes and 
macrophages, and monocyte chemotactic protein-1 (MCP-1) by endothelial cells [38]. 
Nahrendorf and colleagues demonstrated the biphasic migration of monocytes to the heart tissue in 
a mouse model of MI [39]. The first population of monocytes that possess pro-inflammatory properties 
migrate to the site of inflammation via a MCP-1 dependent pathway during the first four days after 
infarction, phagocytose cell debris, produce MMP which degrade the extracellular matrix and express 
pro-inflammatory cytokines TNF-α and IL-1β (Figure 1). The second population of monocytes with 
reparative properties stimulates angiogenesis, expresses TGF-β, IL-10 as well as vascular endothelial 
growth factor (VEGF), and can be found at the site of inflammation starting by day four after MI with 
the recruitment mediated by fractalkine. The turnover of monocytes in the infarcted heart is about 
twenty hours with the death of the majority of cells at the site of inflammation and only a minority of 
undifferentiated monocytes remaining which can be found mainly in the blood and liver, with smaller 
numbers present in the spleen and lymph nodes. The spleen serves as a main source of newly 
differentiated monocytes, and IL-1β plays an essential role in monocytopoesis [40]. Differentiated 
macrophages phagocytose dead cells and cell debris and clear apoptotic neutrophils and cardiac 
myocytes. Apoptotic neutrophils produce factors that inhibit neutrophil recruitment and contribute to 
the production of TGF-β and IL-10 by macrophages [41]. On the other hand, macrophages produce 
cytokines that stimulate fibroblast proliferation, angiogenesis and the production of collagen. The 
differentiated macrophages can be divided into two major subsets: (1) classically activated M1, which 
are stimulated by IFN-γ, and (2) alternatively activated M2, which are induced by IL-4 and  
IL-13 [42,43]. In addition to neutrophils and monocytes/macrophages, dendritic cells (DC) also play 
an important role in the pathogenesis of MI. Anzai and colleagues reported that DC migrate to the site 
of injury reaching their peak concentration at one week following MI and the deletion of DC adversely 
affected left ventricular remodeling and cardiac function. Furthermore, the deletion of DC caused the 
elevation in the expression of pro-inflammatory cytokines and a reduction in the level of  
anti-inflammatory cytokines as well as a shift towards the accumulation of pro-inflammatory 
monocytes/macrophages in the infarcted myocardium [44]. 
T lymphocytes are instrumental in the regulation of the immune response and the response 
following myocardial infarction is no exception. There are two major subtypes of T cells: CD4+ and 
CD8+ lymphocytes. CD4+ T cells can be divided into several populations based on their functional 
activity and cytokine profile: Th1 cells produce IFN-γ and are responsible for the defense against 
intracellular pathogens, Th2 cells secrete IL-4, IL-5 and IL-13 and play a pivotal role in the clearance 
of extracellular parasites, Th17 cells are characterized by IL-17 production and participate in 
inflammation and autoimmunity, and regulatory T cells secrete TGF-β and IL-10 to regulate the 
immune response [45–47]. In contrast, CD8+ T lymphocytes are cytotoxic cells mainly responsible for 
killing infected and tumor cells [48]. Maisel and colleagues demonstrated that the adoptive transfer of 
ex vivo activated splenocytes, isolated from animals with MI, into healthy syngeneic animals’ caused 
myocardial injury with predominantly lymphocyte and plasma cell infiltration. The injury was cardiac 
specific with a good correlation between the infarct size in the donor animals and the size of injury in 
the recipient animals [49]. Interestingly, MI generates cytotoxic T cells that can kill syngeneic 
cardiomyocytes in a MHC dependent manner [50].  
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The induction of MI in the experimental animals showed that the levels of IL-17A and IL-6, which 
can be produced by Th17 cells, were elevated in the infarcted zone compared to the non-infarcted  
zone [51] and the implication of γδT cells in the local production of IL-17A [52]. The importance of 
γδT cells, IL-17A and IL-23 genes in the pathogenesis of MI was demonstrated by using knockout 
mice when the deletion of any of above mentioned parameters improved animal survival and cardiac 
function with the reduction of the infarct size [52]. Furthermore, Hofmann and colleagues reported that 
MI induces the increase in the number of CD3+CD4+ T cells in the myocardium with up-regulation of 
IFN-γ expression, one of the main pro-inflammatory cytokines produced by Th1 cells, and stimulates 
proliferation of both conventional CD4+Foxp3− T cells and regulatory CD4+Foxp3+ T cells in the 
heart-draining lymph nodes. The generation of the adaptive immune response and regulatory T cells 
plays an important role in the resolution of inflammation since MI in CD4 knockout mice 
demonstrated an increase in the number of granulocytes and monocytes/macrophages with  
pro-inflammatory properties in the infarct zone and collagen formation impairment compared to the 
wild type mice with MI [53]. In addition, it has been shown that the impairment in the recruitment of 
CD4+Foxp3+ regulatory T cells to the site of tissue injury, which is mediated via CCR5/MIP, causes 
an increase in the expression of pro-inflammatory cytokines TNF-α, IL-1β and IL-6, and elevates the 
expression as well as activity of MMP which results in an adverse effect on heart tissue  
remodeling [54]. The clinical data demonstrated that there is a shift towards the Th1 immune response 
in patients with acute MI [55], with increased levels of Th1 cells in the blood and IFN-γ in the plasma 
as well as decreased levels of CD4+CD25+Foxp3+ regulatory T cells in the blood and TGF-β in the 
plasma [56]. Moreover, the cells of the immune system contribute to scar tissue formation by 
producing MMP and paracrine factors and by stimulating the migration of fibroblasts [57]. These 
findings demonstrate that in addition to the innate immune system, the adaptive immune system also 
plays a major role in tissue damage, clearance of cell debris, and left ventricular remodeling following 
MI (Figure 1). 
Thus, initiation, development and resolution of inflammation in the heart following MI represent a 
very complex and dynamic process. Consequently, it is crucial to define the balance between 
detrimental and beneficial effects resulting from the innate and adaptive immune responses in injured 
myocardium, presumably through paracrine cross-talk and/or cellular interactions between immune 
cells and various cell populations including cardiac myocytes, endothelial cells, cardiac fibroblasts, 
and resident/circulating stem cells. 
3. Cellular Antioxidant Level Represents a Major Determinant in the Cardiac Regenerative 
Capacity of Stem Cells 
The microenvironment after ischemic injury in the cardiac milieu is deleterious to local cells due to 
oxidative and inflammatory stress, excessive fibrosis, and inadequate angiogenesis [58]. This harsh 
microenvironment has been suggested as a principal reason for a universally low survival rate of 
implanted stem cells [59]. Cell survival is an integral and key component of cell-mediated tissue 
recovery, which can be the result of a reduction in the death of native cells, an increased persistence of 
donor cells, or a combination of the two [60]. 
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Numerous attempts to repair the infarcted heart using exogenous stem cells have been made; 
however, very few of the transplanted donor cells actually survive or engraft long-term, a formidable 
obstacle that needs to be addressed [61]. Alternatively, muscle derived stem cells (MDSCs), a 
CD34+/Sca1+ stem cell population that has been extensively investigated for tissue repair and 
regeneration, restored the heart function and tissue structures (increased angiogenesis, reduced 
ventricular remodeling, and cardiomyocyte differentiation) after ischemic injury more effectively than 
conventional CD56+ myoblasts [62,63]. This is attributed to, at least in part, the greater number of 
MDSCs that survived after 12 weeks post-transplantation as well as the robust paracrine function of 
the MDSCs secreting a number of angiogenic/trophic factors [62]. Nevertheless, it is not clear how the 
MDSCs survived the unfavorable environment following the ischemic cardiac insult more efficiently 
than the CD56+ myoblasts. 
In an attempt to elucidate the mechanism(s) behind MDSC-mediated heart repair, various cellular 
functionalities were examined, including apoptosis under oxidative and inflammatory stress. It was 
found that under conditions of oxidative stress, there were less apoptotic MDSCs than CD56+ 
myoblasts [62]. This indicates that MDSCs are more resistant to oxidative stress-induced apoptosis 
than myoblasts. Inflammatory stress-induced cell death was also examined following TNF-α 
stimulation. The results showed significantly more cell death in the myoblast population compared to 
the MDSC population, highlighting the unique survival advantage of MDSCs over myoblasts under 
stressful conditions [64]. Additional analyses revealed that MDSCs exhibit increased levels of the 
antioxidant glutathione (GSH) and super-oxide dismutase (SOD) as well as decreased levels of ROS 
after exposure to H2O2 [64]. 
To further assess the role of antioxidant capacity after cell transplantation, MDSCs were treated 
with diethyl maleate (DEM), a thiol-depleting agent that decreases GSH levels. The DEM treatment 
resulted in a decreased ratio of MDSC engraftment in skeletal muscles, to a similar level seen in 
myoblast transplantation, indicating that both in vitro and in vivo, antioxidant levels are critical to the 
survival and transplantation efficiency of MDSCs [64]. On the other hand, to investigate whether the 
protection by antioxidant can be augmented, antioxidant levels were increased by treating the MDSCs 
with the glutathione precursor N-acetylcysteine (NAC). It was shown that NAC treatment of MDSCs 
increased their survival under oxidative and inflammatory stress in vitro compared to untreated 
MDSCs while, conversely, treatment with DEM decreased their survival [65].  
Furthermore, MDSCs pre-treated with NAC 24 hours prior to the intramyocardial transplantation 
into the ischemic heart notably increased cardiac contractility, compared to untreated MDSCs. There 
were also improvements in angiogenesis and a reduction of fibrosis. These results indicate that cell 
survival is indeed an important aspect of cellular therapy for cardiac repair. Methods increasing 
survival of transplanted cells, as well as native tissue/cells, may substantially aid in the repair process. 
When the cells are pre-treated with an antioxidant, their capacity to neutralize oxidative species will 
thus increase, which explains their augmented survival. Other studies have also indicated that cell 
survival is a key to cardiac cell therapy. Though mesenchymal stem cells have been shown to promote 
functional and histological improvements after myocardial infarction, when the cells were transduced 
with the survival factor Akt, this improvement was significantly increased [66]. On another note, 
VEGF, a potent angiogenic factor, has also been shown to exert a protective effect on the surrounding 
cardiomyocytes [67]. Consequently, the cell survival and paracrine function of MDSCs appear to be 
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two independent yet inter-related areas where further improvements can be made to further improve 
cardiac cell therapy.  
Similarly, when preconditioned with Carvedilol, which is a nonselective β-blocker with 
independent antioxidant properties for scavenging superoxide anions and hydroxyl radicals, treated 
MSCs exhibited significant protection against H2O2-induced oxidative stress and cell death, compared 
with untreated cells [68]. Furthermore, transplantation of MSCs with adjuvant treatment of Carvedilol 
following MI resulted in significant improvement in cardiac function, decreased fibrosis, and reduced 
cellular apoptosis when compared with the MSC-only group. Additionally, the paracrine mechanism 
by which MSCs protect cardiomyocyte following ischemia/reperfusion (I/R) injury was further 
demonstrated by Desantiago et al. using an in vitro model of I/R [69]. Reperfusion of mouse 
cardiomyocytes with MSC-conditioned tyrode (MSC-ConT) led to a decreased number of attenuated 
cardiomyocyte shortening that resulted from depolarization of mitochondrial membrane potential and 
subsequent increase of diastolic Ca2+ as well as prolonged cardiomyocyte survival. The antioxidant 
capacity of MSC-ConT can be tied, at least partly, to the presence of extracellular superoxide 
dismutase (SOD3) in the solution, reducing reperfusion-induced ROS production. 
4. Mesenchymal Stem Cells as Immunomodulators in Cardiac Repair 
Mesenchymal stem cells (MSCs), which were initially identified in the bone marrow but can be 
found and isolated from umbilical cord, placenta, adipose, muscle and other tissues, have attracted the 
attention of scientists and clinicians as a good source for stem cell-mediated therapy for the following 
three main reasons. First, MSCs can differentiate into a number of different cell types including 
cardiac myocytes, endothelial cells, osteoblasts, chondrocytes and adipocytes [70–74]. Second, MSCs 
are immunoprivileged because of high expression of immunomodulatory MHC-Ib and low or no 
expression of immunogenic MHC-Ia, MHC-II and co-stimulatory molecules [75,76]. In addition, 
MSCs possess strong immunosuppressive properties that are mediated via a cell contact-dependent 
mechanism and production of soluble factors such as prostaglandin E2, nitric oxide, hepatocyte growth 
factor, TGF-β1, IL-10, indoleamine 2,3-dioxygenase and heme oxygenase-1 [77–81]. However, MSCs 
become immunogenic after differentiation because of the down-regulation of MHC-Ib and up-regulation 
of MHC-Ia and MHC-II [76]. Third, MSCs have the ability to migrate to the site of injury and repair 
the tissue [82,83]. This section of the review is dedicated to the immunomodulatory properties of 
MSCs in cardiac repair, particularly following acute MI, although their mechanisms of action are 
complex and still not fully understood. The immunomodulatory effect of MSCs is mainly mediated by 
paracrine factors because only a minority of injected stem cells is present in the heart tissue [84]. 
Human MSCs prolong the survival of neutrophils that is mediated by IL-6 with subsequent 
stimulation of STAT-3 [85,86] and inhibit ROS production, particularly hydrogen peroxide, by 
stimulated neutrophils that is mediated by IL-6 without affecting their phagocytic and chemotactic 
activities [86]. A direct myocardial injection of cells that contain human mesenchymal and 
hematopoietic progenitor cells significantly reduced the number of neutrophils at an earlier time point 
compared to the control group in a rat experimental model of MI [87]. Moreover, the reduction in the 
number of recruited neutrophils is probably mediated by a decrease in the levels of pro-inflammatory 
cytokines such as IFN-γ, TNF-α and IL-1 in the group of animals injected with MSCs.  
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The systemic administration of human MSCs in the experimental model of acute MI causes a 
reduction in the total number of monocytes/macrophages in the cardiac tissue. However, the number of 
CD206+ and F4/80+ cells increased in the group of animals that received MSCs. The increase in the 
number of alternatively activated/anti-inflammatory macrophages may be mediated by an increase of 
IL-10 expression and a decrease in the expression of IL-1β and IL-6 at the site of cardiac injury [88]. 
The in vitro data are consistent with the data obtained on experimental animals and demonstrated that 
human MSCs decrease the number of classically activated mouse bone marrow derived Ly6C+ 
macrophages and increase the number of alternatively activated CD206+ macrophages, the latter effect 
is mediated by IL-10 [88]. In addition, the in vitro analyses using MSCs and macrophages from the 
same species confirmed the data obtained on experimental animals. Indeed, mouse MSCs increased the 
production of IL-10 and IL12p40 while the production of IFN-γ, TNF-α, IL-6 and IL12p70 by 
activated peritoneal macrophages decreased. The modulatory effect of MSCs was dependent on  
cell-cell contact and soluble factors, which was partially mediated by prostaglandin E2. Furthermore, 
mouse MSCs polarized macrophages towards the alternatively activated phenotype with increased 
phagocytic activity of apoptotic cells and caused the impairment of antigen-presenting capacity [89]. 
Similar results were reported by other groups using human MSCs and human macrophages. The 
incubation of human MSCs with human macrophages polarized macrophages toward the alternatively 
activated/anti-inflammatory phenotype with up-regulation of CD206, CD163 and CD16 as well as the 
increased secretion of IL-4, IL-10, IL-13 and VEGF, while the levels of IFN-γ, TNF-α, IL-1α, IL-12, 
IL-17 and IL-23 were decreased [90]. The polarization effect of MSCs on macrophages in these 
experiments was mediated by IL-6. Kim and colleagues demonstrated that the polarization of 
monocyte-derived macrophages towards the CD206+ phenotype under the influence of MSCs is 
mediated by both direct cell-cell contacts and soluble factors [91]. The incubation of human MSCs 
with stimulated macrophages further increased the intra-cellular levels of IL-10 and IL-6 compared to 
the control group. In addition, IFN-γ and TNF-α stimulated human MSCs induced the polarization of 
CD14+ monocytes towards the CD206+ phenotype with significant IL-10 up-regulation, and blocking 
indoleamine 2,3-dioxygenase partially reduced IL-10 production [92]. 
There are a number of published papers on the influence of MSCs on adaptive immunity, 
particularly on T cells, following MI. Indeed, the number of CD3+ and CD4+ T cells decreased at 24 
and 72 h after direct myocardial injection in animals that received a population of cells containing 
mesenchymal and hematopoietic progenitor cells [87]. Similar results were obtained by Burchfield and 
colleagues who reported that intra-myocardial injection of mouse bone marrow derived mononuclear 
cells (BM-MNCs) into the mice with MI significantly reduced CD3+ T cell recruitment, which is 
mediated by IL-10 produced by BM-MNCs [93]. The in vitro analysis showed that IFN-γ and TNF-α 
treated human MSCs suppress the proliferation of nonspecifically stimulated human CD3+ T cells that 
is directly mediated by indoleamine 2,3-dioxygenase, which catalyzes tryptophan degradation, an 
important amino acid required for T cell proliferation, and indirectly via the generation of alternatively 
activated macrophages, which produce IL-10 [92]. In addition to the immunosuppressive ability of 
MSCs on the T cell population, MSCs contribute to the generation of regulatory T cells. Human MSCs 
stimulate the generation of CD4+CD25+Foxp3+ regulatory T cells in allogeneic culture of purified 
human CD4+ T cells, which is mediated through a contact-dependent mechanism and the production 
of soluble factors such as PGE2 and TGF-β, although the presence of soluble factors alone is not 
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sufficient for the generation of regulatory T cells [94]. Similarly, human MSCs contribute to regulatory 
T cell generation, which is mediated via the Notch1 signaling pathway [95], and maintain their 
suppressive activity in a mixed lymphocyte reaction [96]. In the experimental model of acute MI, the 
adoptive transfer of CD4+CD25+ regulatory T cells improved left ventricular contraction and cardiac 
function, which may be mediated by the local reduction of IFN-γ levels [97], and by the decrease in 
the recruitment of neutrophils, macrophages and lymphocytes as well as by the down-regulation of 
TNF-α and IL-1β expression and elevation of IL-10 at the site of injury [98]. Moreover, CD4+CD25+ 
regulatory T cells suppress cytotoxic T lymphocyte-mediated lysis of cardiac myocytes and inhibit 
apoptosis of cardiomyocytes via a contact-dependent mechanism and IL-10 production [98]. 
In addition to various growth factors and cytokines produced by MSCs, exosomes recently attracted 
the attention of researchers. Exosomes are small extracellular vesicles that are secreted by a number of 
cell types and contain RNAs and proteins, which can affect various biological functions. It has been 
demonstrated that exosomes derived from MSCs reduce infarct size, decrease oxidative stress and cell 
death in an experimental model of myocardial infarction/reperfusion injury [99,100]. Taken together, 
the reviewed data indicate that MSCs, through cell-cell contact mechanisms and/or production of 
soluble factors, create an environment that suppresses ROS production by neutrophils, polarizes 
monocytes/macrophages towards an alternatively activated/anti-inflammatory phenotype, inhibits 
proliferation and generation of effector T cells as well as contributes to the increase in the number of 
regulatory T cells, and as a result, prevents adverse left ventricular remodeling, promotes angiogenesis 
and improves cardiac function.  
5. Human Blood Vessel-Derived Stem Cells for Cardiac Repair and Regeneration 
Blood vessels throughout the human body are typically composed of three structural layers: intima, 
media, and adventitia [101]. At the microvascular level, the structure of the vascular wall is reduced to 
only endothelial cells (ECs) and surrounding perivascular stromal/mural cells, i.e., pericytes [102]. It 
has been suggested that pericytes (PCs) as well as other vascular cell population(s) represent an origin 
of adult multipotent stem/progenitor cells [103–106]. Recently, our group and other laboratories have 
successfully identified several subpopulations of multi-lineage precursor cells within the human 
vasculature, including myogenic endothelial cells (MECs), PCs, and adventitial cells (ACs) [106–108]. 
Collectively we named these three precursor subpopulations, “human blood-vessel-derived stem cells 
(hBVSCs)”. These subsets of hBVSCs can be purified from blood vessels using fluorescence-activated 
cell sorting (FACS), based on their unique profiles of cell surface markers, and share striking 
similarities to typical mesenchymal stem/stromal cells in culture [105]. Specifically within the human 
skeletal muscle, MECs and PCs can be identified and isolated from the microvasculature [105–107]. 
Purified MECs and PCs have been shown to repair/regenerate injured and/or genetically defective 
tissues more efficiently than vascular ECs and/or conventional CD56+ myoblasts [106,107]. In this 
section, we summarize the recent progress in the translational applications of MECs and PCs in 
cardiovascular regenerative medicine. 
MECs, a putative developmental intermediate between ECs and myogenic cells (MCs), have been 
proposed as the human counterpart of murine MDSCs due to their similar anatomical localization and 
scarcity in situ as well as versatile regenerative functionality [109]. MECs not only express MC 
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markers such as CD56 and Pax7, but also express EC markers including CD34, CD144 (VE-cadherin), 
von Willebrand factor (vWF), and Ulex europaeus agglutinin-1 (UEA-1) [107,110]. Though present at 
a very low frequency in situ, MECs (CD34+/CD56+/CD144+/CD45−) can be purified by FACS to 
homogeneity. MECs can be expanded efficiently in long-term culture, at the clonal level, and  
exhibit myogenic, adipogenic, osteogenic, and chondrogenic developmental potentials in vitro  
and in vivo [107,109,110]. MECs have also been shown to participate in angiogenesis/vasculogenesis 
in vitro and in vivo [109]. The regenerative capacity of MECs in the cardiac milieu has been 
demonstrated by Okada and colleagues in an ischemic injury model [63]. When transplanted 
intramyocardially into the ischemic hearts of immunodeficient mice, MECs restored cardiac contractile 
function more effectively than conventional CD56+ MCs and ECs as is observed with murine  
MDSCs [62]. Histological analyses showed a significant reduction in cardiac fibrosis and cellular 
apoptosis as well as augmented angiogenesis and cell proliferation in MEC-injected hearts. These 
beneficial effects have been largely attributed to the paracrine function of MECs, especially the 
elevated secretion of VEGF under hypoxia. Nevertheless, transplanted MECs generated robust 
engraftments and a small number of donor cell-derived cardiomyocytes within the ischemic 
myocardium, indicating the role of cell survival and differentiation in MEC-mediated cardiac repair [63]. 
PCs are microvascular mural cells commonly known for their vascular regulatory and supportive 
functions [111–113], and PC-EC interactions modulate EC proliferation and vascular  
remodeling [114–116]. Nevertheless, the lack of homogeneous PCs in the past hindered further 
investigations to explore their regenerative potential. Using similar immunohistochemical and flow 
cytometry strategies, our group identified and purified PCs from multiple human tissues based on the 
expression of CD146 (Mel-CAM), NG2 (chondroitin sulphate), platelet-derived growth factor 
receptor-beta (PDGFRβ), alkaline phosphatase (ALP), with the absence of myogenic (CD56), 
hematopoietic (CD45), and endothelial (CD31, CD34, and CD144) cell surface markers [106]. 
Interestingly, only PCs surrounding microvessels (arterioles and venules), but not those around most 
capillaries, expressed alpha-smooth muscle actin (a-SMA). PCs, natively and in culture, displayed 
typical MSC differentiation capacities and expressed classic MSC markers: CD44, CD73, CD90 and 
CD105, indicating their developmental role as precursors of MSCs [106]. The potential applications of 
FACS-purified PCs (CD146+/CD34−/CD45−/CD56−) in cardiovascular diseases have recently been 
investigated [117,118]. When transplanted into ischemic hearts of immunodeficient mice, PCs derived 
from human skeletal muscle were shown to notably improve cardiac contractility and attenuate left 
ventricular dilatation, superior to CD56+ MCs, for up to 8 weeks [117]. Histological analyses revealed 
considerable structural recovery in PC-treated hearts, including increased host angiogenesis and 
substantial reduction of chronic inflammation and myocardial fibrosis at the infarct site. The beneficial 
effects of PC treatment were attributed to the robust paracrine function of PCs and, to a lesser extent, 
their direct cellular involvement including perivascular homing, direct interactions with host cells, and 
differentiation into cardiac cell types [117]. Moreover, PCs were seeded onto small-diameter,  
bi-layered elastomeric scaffolds to investigate their vascular reparative capacity [118]. After 
implantation for 8 weeks in Lewis rats, PC-seeded aortic interposition grafts showed a significantly 
higher rate of vessel patency than unseeded controls and exhibited favorable tissue remodeling 
including the presence of multiple layers of smooth muscle cells, elastin deposition, and 
endothelialization in the lumen, suggesting the potential of PCs in vascular tissue engineering. 
Int. J. Mol. Sci. 2013, 14 16269 
 
 
Apart from MECs and PCs, another distinct subset of hBVSCs, i.e., ACs, which resides in the 
adventitia of human vasculature, has recently been described as a putative pericyte progenitor 
population [108,119,120]. Campagnolo and colleagues and Katare and colleagues respectively 
reported that ACs (CD34+/31−) derived from adventitial vasa vasorum of human saphenous vein exert 
significant therapeutic efficacy in murine ischemic limbs and infarcted hearts, owing primarily to their 
robust angiogenic/vasculogenic and angiocrine capacities [119,120]. On the other hand, applying the 
same pre-plating technique used for murine MDSC isolation, our group recently reported the isolation 
of human slowly adhering cells (hSACs) and explored their therapeutic effect in the ischemic mouse 
heart [121]. hSACs not only exhibited significantly greater survival under oxidative and inflammatory 
stress than their rapidly adhering counterparts, but also notably promoted functional and structural 
recovery of ischemic hearts [121]. Altogether these data indicate robust therapeutic capacities of 
hBVSC subsets and mMDSC counterparts in cardiovascular regenerative medicine. 
6. The Role of Human Pericytes in Antioxidation and Immunomodulation  
PCs, also known as mural or Rouget cells, are located around endothelial cells in the blood 
microvessels, incompletely surrounding them, and play a major role in promoting the survival, 
adhesion and mechanical stabilization of endothelial cells. Moreover, PCs are essential in tissue repair 
and fibrosis, the development and maintenance of the blood brain barrier, diabetic retinopathy and 
cancer development [102,122]. In this section, we will review the role of human PCs in antioxidation 
and immunomodulation. 
Using purified MECs and PCs from the same donor, we are currently investigating the antioxidative 
capacities of these two hBVSC subpopulations under simulated oxidative stress conditions induced by 
hydrogen peroxide (H2O2). Our preliminary results showed that PCs proliferated at a higher rate than 
MECs when stimulated with H2O2 (100 and 250M) while more MECs survived in a higher 
concentration of H2O2 (400 μM) than the PCs, implicating differential cellular antioxidation in MECs 
and PCs (Chen and Saparov, unpublished results) [64]. Regarding the published data on the role of 
PCs in immunomodulations, Stark and colleagues reported [123] that TNF-α and LPS stimulated 
human placental PCs up-regulated the expression of TLR2, TLR4, TNF receptor and NLRP3 (NLR 
family, pyrin domain containing 3). The stimulation of PCs by DAMPs as well as TNF-α and LPS also 
elevated the expression of ICAM-1 on the surface of PCs that is used to bind neutrophils and 
monocytes via β2-integrins. The analysis of cytokine and chemokine mRNA expression by human 
placental PCs showed that they constitutively expressed IL-6, macrophage migration inhibitory factor 
(MIF) and the following chemokines: CXCL1, CXCL8 and CCL2. The stimulation of PCs by DAMPs, 
as well as with TNF-α and LPS, up-regulated the expression of all cytokines and chemokines;although 
the levels of up-regulation depended on the stimulus. Moreover, the human placental PCs 
constitutively express NF-κB and IL-1β, and stimulation with TNF-α increased their expression. The 
analysis of protein production demonstrated that un-stimulated PCs produced detectable levels of MIF, 
CXCL1, CXCL8 and CCL2. Both TNF-α and LPS increased MIF production as early as 6 h after 
stimulation by LPS. However, lysate of necrotic cells increased MIF production 1 h after stimulation, 
which is indicative of MIF pre-existence within the PCs. Furthermore, the secretion of chemokines 
was also elevated after stimulation. The combination of secreted MIF and ICAM-1 expressed on the 
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surface of PCs are crucial for their interaction with neutrophils and monocytes via integrins expressed 
on the surface of these cells. The analysis of factors, which are secreted by human placental PCs and 
are necessary for the in vitro migration of neutrophils and monocytes, revealed that MIF and CXCL8 
are required for neutrophil migration, while MIF in combination with CCL2 are implicated in 
monocyte migration. In addition, TNF-α stimulated PCs activated both neutrophils and monocytes to 
up-regulate mRNA expression of TLR, MMP and integrins as well as increased the surface  
expression of CD69 on monocytes, CD11b on neutrophils and extended neutrophil survival [123,124].  
These experiments indicate that PCs express pattern recognition receptors to DAMPs and  
pathogen-associated molecular patterns (PAMPs) and their activation causes the secretion of cytokines 
and chemokines, some of which are capable of activating neutrophils and monocytes, and influencing 
their migration which demonstrates the important role of PCs in innate immunity. 
Maier and Pober demonstrated [125] that human placental PCs express MHC class I, ICAM-1,  
PD-L1, PD-L2 without MHC class II and co-stimulatory molecules (CD80 and CD86) expression. The 
stimulation with IFN-γ in addition, to further increase the expression of MHC-I, ICAM-1, PD-L1 and 
PD-L2, also up-regulated the expression of MHC-II. Similar results were reported by Verbeek and 
colleagues using human brain PCs, that in addition to MHC-I and ICAM-1, un-stimulated human brain 
PCs also express VCAM-1, and stimulation with TNF-α further up-regulated the expression of all 
three markers. The authors also demonstrated that VLA-4/VCAM-1 is important for T cell interaction 
with human brain PCs [126]. The experiments with co-culturing placental PCs with allogeneic CD4+ 
T cells showed that IFN-γ pre-stimulated PCs activated CD4+ T cells to up-regulate the activation 
markers, CD25 and CD69, to produce very low but detectable levels of IFN-γ and IL-2 without 
entering into the cell cycle, compared to the un-stimulated PCs. As a result, it caused CD4+ T cells to 
enter into an anergic state with up-regulation of genes associated with human T cell anergy. However, 
IFN-γ pre-stimulated PCs are capable of inducing allogeneic CD4+ T cell proliferation if these  
cells are pre-activated with autologous to PCs cells, which indicate that PCs can activate the 
effector/memory cells. In addition, both IFN-γ stimulated and un-stimulated placental PCs suppress the 
CD4+ T cell response to allogeneic cells in a transwell system that is partially inhibited by TGF-β and 
IL-10 [125,127]. Tu and colleagues also reported that human retinal PCs inhibit the proliferation of 
activated CD4+ T cells [128]. Our preliminary data showed that un-stimulated human PCs, which  
were isolated from human skeletal muscle based on the expression of the reported phenotype 
CD146+/CD34−/CD45−/CD56−, secrete MCP-1 [129]. Both oxidative stress and inflammatory 
stimulus with LPS further increased MCP-1 production by human PCs while secretion of TGF-β by 
un-stimulated PCs slightly increased after exposure to oxidative stress in vitro, implicating the role of 
microenvironmental stimulation on the immunomodulatory function of PCs (Chen and Saparov, 
unpublished results). Overall, the published data demonstrate that human PCs can influence both 
innate and adaptive immune responses via a cell-cell contact mechanism and by producing soluble 
factors such as IL-1, IL-6, MIF as well as several chemokines, and can be a good source for stem  
cell-mediated therapy. 
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7. Conclusions  
The lack of oxygen and nutrients following MI triggers a complex and dynamic process that 
involves the resident cells at the site of infarction, as well as the recruited cells from the circulation and 
other organs, generating inflammation and oxidative stress and further causing cardiac tissue damage, 
repair and heart remodeling. Both innate and adaptive immune systems play pivotal roles in this 
process by producing pro-inflammatory cytokines, reactive oxygen species, proteolytic enzymes as 
well as chemokines. In addition to damaging cardiac tissue, the cells of the immune system actively 
clean the site of infarction, resolve inflammation, promote angiogenesis and participate in heart 
regeneration. Stem cell therapy diminishes the detrimental effect caused by the immune system and 
contributes to resolving inflammation, as well as improving cardiac function. Understanding the 
crosstalk between cellular parties involved in this process will facilitate the enhancement of therapeutic 
approaches in improving cardiac regeneration, potentially eliminating heart failure and reducing 
mortality following MI. 
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